## WHAT IS CLAIMED IS:

## 1. Compounds of the formula (I)

N — Linker — Support  $M^{m+} \qquad (An \quad {}^{q})_{p} \qquad (I)$ 

5

where

N

Linker

is an enantiomerically enriched chiral nitrogen compound,

is a radical which is bonded both covalently to the enantiomerically enriched chiral nitrogen compound and to the support,

Support

is a micro-, meso- or macroporous support material,

15

10

 $(M^{m+})$ 

is a metal having valency m

L

is an anionic or uncharged ligand

n

is one, two, three or four

20

(An q-)

is an anion having valency q and

p

is (m – number of anionic ligands L)/q.

## 2. Compounds according to Claim 1, characterized in that



is an enantiomerically enriched chiral nitrogen compound of the formula (II)

5

$$\begin{array}{c}
R^2 \\
N - R^3 - N
\end{array}$$
(II)

where

the arrow indicates the bonding point to the linker and

10

- $R^1$ ,  $R^2$  and  $R^4$  are each independently hydrogen,  $C_1$ - $C_8$ -alkyl,  $C_5$ - $C_{15}$ -arylalkyl or  $C_4$ - $C_{14}$ -aryl or  $NR^1R^2$  as a whole is a cyclic amino radical having a total of 4 to 20 carbon atoms,
- 15 R<sup>3</sup> is a divalent radical having 2 to 30 carbon atoms or
  - R<sup>3</sup> and at least one of the radicals R<sup>1</sup>, R<sup>2</sup> and R<sup>4</sup> together are part of a cyclic amino radical having a total of 4 to 20 carbon atoms.
- 20 3. Compounds according to Claim 2, characterized in that R<sup>1</sup>, R<sup>2</sup> and R<sup>4</sup> are each independently hydrogen, C<sub>1</sub>-C<sub>8</sub>-alkyl, C<sub>5</sub>-C<sub>15</sub>-arylalkyl or C<sub>4</sub>-C<sub>14</sub>-aryl or NR<sup>1</sup>R<sup>2</sup> as a whole is a 5- or 6-membered monocyclic amino radical which is optionally mono-, di-, tri- or tetrasubstituted on the carbon framework by C<sub>1</sub>-C<sub>4</sub>-alkyl and

 $R^3$  is a divalent radical which is selected from the group of  $C_2$ - $C_8$ -alkylene which may optionally be further mono- or diubstituted by  $C_4$ - $C_{14}$ -aryl radicals,  $C_5$ - $C_{15}$ -arylalkylene,  $C_4$ - $C_{14}$ -arylene or bis( $C_4$ - $C_{14}$ -arylene) or

5

 $R^3$  and one of the radicals  $R^1$ ,  $R^2$  and  $R^4$  together are part of a 5- or 6-membered monocyclic amino radical which is optionally additionally mono-, di-, tri- or tetrasubstituted on the carbon framework by  $C_1$ - $C_4$ -alkyl.

10

- 4. Compounds according to Claim 1, characterized in that the support is a micro- or mesoporous support material.
- 5. Compounds according to Claim 1, characterized in that the supports are silica gels or zeolites of the MOR, X, Y, MCM, ZSM, FAU, MFI, L, BEA, FER, A and SBA type or those of the AlPO, MAlPO and SAPO type, and the zeolites are optionally isomorphically substituted.
- 6. Compounds according to Claim 1, characterized in that supports are mesoporous zeolites.
  - 7. Compounds according to Claim 1, characterized in that (M <sup>m+</sup>) is cobalt in the formal oxidation states 0, +2 and +3, rhodium and iridium in the formal oxidation states +1 and +3, nickel, palladium and platinum in the formal oxidation states 0 and +2 or ruthenium in the formal oxidation state +2.
  - 8. Compounds according to Claim 1, characterized in that L is the following types of ligand: monoolefins, diolefins, nitriles, aromatics or anionic ligands.

- 9. Compounds according to Claim 1, characterized in that (An q-) is nitrate, perchlorate, sulphate, hexafluorophosphate, hexafluoroantimonate, hexachloroantimonate, borates or sulphonates.
- 10. Compounds according to Claim 1, characterized in that they are of the formulae (Ia), (Ib), (Ic) and (Id)

where, in each case,

\* marks a stereogenic centre which is either R- or S-configured, with the proviso that mesoforms are excluded (compounds of the formula (Ic) and (Id))

M<sup>+</sup> is rhodium<sup>I</sup> or iridium<sup>I</sup> and

L is cod or nbd and

An- is perchlorate, hexafluorophosphate, trifluoromethanesulphonate or tetrafluoroborate.

## 11. Compounds of the formula (V)

15

10

5

where

NN

is an enantiomerically enriched chiral nitrogen compound,

Linker

is a radical which is bonded both covalently to the enantiomerically enriched chiral nitrogen compound and to the support,

5

Support is a micro-, meso- or macroporous support material which is modified by the linker.

- 10 12. Catalysts comprising compounds according to Claim 1.
  - 13. A process for conducting asymmetric reactions comprising catalyzing the reactions with compounds of Claim 1.
- 15 14. Process for catalytically preparing enantiomerically enriched compounds, comprising catalyzing the preparation with the compounds according to Claim 1.
- Process according to Claim 14, characterized in that processes for preparing enantiomerically enriched compounds are asymmetric hydrogenations.
  - 16. Process according to Claim 14, characterized in that asymmetric hydrogenations are hydrogenations of  $\alpha$  and  $\beta$ -ketocarboxylic esters.

25

17. Process according to Claim 16, characterized in that  $\alpha$ - and  $\beta$ ketocarboxylic esters are those of the formula (VII)

$$R^{5}$$
 $R^{6}$ 
 $R^{7}O$ 
 $O$ 
 $(VII)$ 

where

5

 $R^5$  and  $R^7$  — are each independently  $C_1\text{-}C_{12}\text{-}alkyl,\ C_1\text{-}C_{12}\text{-}haloalkyl,}$   $C_5\text{-}C_{15}\text{-}arylalkyl\ or\ C_4\text{-}C_{14}\text{-}aryl\ and}$ 

 $R^6$  is absent or is 1,1-( $C_1$ - $C_4$ -alkylene).

- 18. Process according to Claim 15, characterized in that the reaction temperature in the case of asymmetric hydrogenations is 0 to 200°C and the partial hydrogen pressure is 0.1 to 200 bar.
- 19. Process according to Claim 15, characterized in that solvents selected from the group consisting of aliphatic or aromatic, optionally halogenated, hydrocarbons, ethers and alcohols are used in the process.
- 20. Process according to Claim 14, characterized in that the weight ratio of compounds to substrate is 1:1 to 1:10 000.
  - 21. A process for preparing optical resolution reagents comprising providing compounds which have been prepared by a process according to Claim 14.
- 25 22. A process for preparing agrochemicals or pharmaceuticals comprising providing compounds which have been prepared by a process according to Claim 14.